The global hypoactive sexual desire disorder treatment market grew at a CAGR of around 6% during 2014-2019. Hypoactive sexual desire disorder (HSDD) refers to a medical condition with low libido or sexual desire in women. The sexual dysfunction in HSDD is primarily associated with hyperfunction inhibition and hypofunctional excitation regulated by neuromodulators in the brain. Furthermore, several physical conditions are also related to HSDD, including anxiety, depression, diabetes, urinary incontinence, menopause, multiple sclerosis, etc. HSDD treatment mainly includes psychotherapy or pharmacotherapy. Psychotherapy utilizes cognitive behavioral therapy, which offers counseling sessions with a sex therapist, whereas pharmacotherapy comprises of treatment with several drugs, such as Buspirone, Bupropion, Testosterone, Flibanserin, etc.
The rising working women population coupled with their hectic work schedules often result in low libido conditions, thereby augmenting the demand for HSDD treatment. Furthermore, the high prevalence of numerous lifestyle ailments, such as anxiety, stress, depression, prolonged fatigue, irregular menstruation, etc., is also catalyzing the incidences of HSDD. Additionally, diminished libido can also be a side-effect of certain chemical-based drugs that may further lead imbalance of neurotransmitters in the brain, causing HSDD. Moreover, the rising aging women population, premature menopause, and low self-esteem towards one’s physical appearance is also associated with low libido in women, thereby driving the demand for HSDD treatment. Besides this, the reducing stigma associated with HSDD coupled with the growing awareness towards the disease diagnosis and effective treatment is further propelling the market growth. The emergence of the PLISSIT model (Permission, Limited Information, Specific Suggestions, and Intensive Therapy) aids in the initial screening of HSDD. Furthermore, the faster drug approvals for treating HSDD along with the increasing investments in new drug development activities are further catalyzing the market growth. For instance, the U.S. Food and Drug Administration (FDA) approved ‘Vyleesi’ that activates melanocortin receptors for improving sexual desire in women. Looking forward, the IMARC Group expects the global hypoactive sexual desire disorder treatment market to continue its moderate growth during the next five years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hypoactive sexual desire disorder treatment market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, therapy, distribution channel and application.
Breakup by Therapy:
Breakup by Distribution Channel:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Allergan Plc, AMAG Pharmaceuticals, Inc., Emotional Brain BV, Endoceutics, Inc., GlaxoSmithKline Plc, Ovoca Bio Plc, Pivot Pharmaceuticals, Inc., Palatin Technologies, Inc., S1 Biopharma, Inc., and Sprout Pharmaceuticals, Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at